Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Non-Current Debt (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Non-Current Debt for 10 consecutive years, with $385.0 million as the latest value for Q4 2025.

  • Quarterly Non-Current Debt changed 0.0% to $385.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $385.0 million through Dec 2025, changed 0.0% year-over-year, with the annual reading at $385.0 million for FY2025, 0.0% changed from the prior year.
  • Non-Current Debt hit $385.0 million in Q4 2025 for Ironwood Pharmaceuticals, roughly flat from $385.0 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $425.0 million in Q2 2024 to a low of $275.0 million in Q1 2024.
  • Historically, Non-Current Debt has averaged $368.2 million across 3 years, with a median of $385.0 million in 2024.
  • Biggest YoY gain for Non-Current Debt was 40.0% in 2025; the steepest drop was 9.41% in 2025.
  • Year by year, Non-Current Debt stood at $300.0 million in 2023, then increased by 28.33% to $385.0 million in 2024, then changed by 0.0% to $385.0 million in 2025.
  • Business Quant data shows Non-Current Debt for IRWD at $385.0 million in Q4 2025, $385.0 million in Q3 2025, and $385.0 million in Q2 2025.